Soligenix announces Marco Maria Brughera as member of its Board of Directors
"We are pleased to welcome Dr. Brughera to the Soligenix Board," President and Chief Executive Officer of Soligenix Christopher J. Schaber said. "As Soligenix looks to advance its pipeline, we intend to leverage Dr. Brughera's extensive experience in research and development, portfolio optimization and business development. We believe his outstanding record of achievement will add significantly to our already diverse and experienced Board of Directors and management team."
Brughera has held positions as corporate research and development managing director and president of research for the Sigma-Tau Group since January 2011. He previously served as vice president of preclinical development at Nerviano Medical Sciences from 2004 to 2010.
"We look forward to his contributions to our future success, particularly as we move forward with our infectious disease and biodefense programs, including the development of OrbeShield in GI ARS under our recent BARDA and NIAID contract awards of up to $26.3M and $6.4M, respectively," Schaber said.
Soligenix is a clinical stage biopharmaceutical company that develops products to treat inflammatory diseases and defend against biological agents.